Disease · MONDO_0810000
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Brolucizumab 6mg vs Aflibercept 2mg: deaths from any cause | 4 of 370 | 7 of 369 | 739 | NCT02434328 | Trial comparisons |
| Brolucizumab 6mg vs Aflibercept 2mg: serious adverse events | 79 of 370 | 89 of 369 | 739 | NCT02434328 | Trial comparisons |
| Ranibizumab Non-ANCHOR vs Ranibizumab ANCHOR: serious adverse events | 80 of 513 | 4 of 18 | 531 | NCT00331864 | Trial comparisons |
| Verteporfin + Ranibizumab vs Ranibizumab: serious adverse events | 25 of 122 | 28 of 133 | 255 | NCT00433017 | Trial comparisons |
| Ranibizumab vs Sham Control: Number of Participants With Requirement for Rescue Treatment at Month 1 | 0 of 119 | 1 of 58 | 177 | NCT01840410 | Trial comparisons |
| Group I vs Group II: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT00527475 | Trial comparisons |
| Group I vs Group II: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT00527475 | Trial comparisons |
| ICON-1 Maintenance Therapy vs ICON-1 Combination Therapy: deaths from any cause | 0 of 7 | 0 of 8 | 15 | NCT03452527 | Trial comparisons |
| ICON-1 Maintenance Therapy vs ICON-1 Combination Therapy: serious adverse events | 2 of 7 | 1 of 8 | 15 | NCT03452527 | Trial comparisons |
Ranibizumab Dose A vs Ranibizumab Dose B: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart Measured at 4 Meters. | 5 of 5 | 2 of 2 | 7 | NCT00363168 | Trial comparisons |
| Ranibizumab Dose A vs Ranibizumab Dose B: Number of Subjects Experiencing Complications Related to Drug or Its Administration | 0 of 5 | 0 of 2 | 7 | NCT00363168 | Trial comparisons |
| Ranibizumab Dose A vs Ranibizumab Dose B: serious adverse events | 0 of 5 | 0 of 2 | 7 | NCT00363168 | Trial comparisons |
| Dexamethasone and Ranibizumab vs Ranibizumab and Sham: serious adverse events | 0 of 2 | 0 of 2 | 4 | NCT01122511 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0810000/comparisons